OM DETTA AVSNITT
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to discuss the company's third-quarter 2026 financial results, which showed a narrower net loss and lower general and administrative expenses as Medicus shifts its development focus towards CD228V, an antibody-drug conjugate licensed from Pfizer.
For the three months ended September 30, 2026, Medicus reported a net loss of $15.2 million, or $11.64 per share, compared with a loss of $16 million, or $56.18 per share, in the same period last year.
Medicus ended the quarter with $13.1 million in cash, cash equivalents and restricted cash, including $5 million in unrestricted cash and cash equivalents.
Bokhari said the third quarter marked a transformation for Medicus into a precision oncology-focused biotechnology company, with CD228V now its principal development priority. Medicus holds an exclusive worldwide licence to develop, manufacture and commercialize CD228V through a co-development agreement with Pfizer, which has provided $2 million in development funding.
The company is targeting initial clinical proof-of-concept in patients with relapsed, refractory or immunotherapy-resistant melanoma. The program is supported by an existing US investigational new drug application and a first-in-human Phase 1 study.
Medicus believes CD228V could potentially achieve an objective response rate above 30% in melanoma, although that target has yet to be demonstrated in clinical trials. Pfizer also has the option to fund all or part of development costs beginning with the first pivotal trial.
Medicus is also advancing plans to separate its SkinJect business through a proposed business combination with a special purpose acquisition company.
Meanwhile, for Teverelix, the company has submitted a proposed seamless Phase 2b/3 clinical trial protocol to the US Food and Drug Administration for advanced prostate cancer. The study is designed to enrol approximately 608 patients, subject to meeting predefined criteria to proceed.
Rather than fund the Teverelix study itself, Medicus intends to pursue an out-licensing agreement or another strategic partnership to advance the program.
#proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #CD228V #PrecisionOncology #Biotechnology #CancerResearch #Melanoma #Pfizer #SkinJect #Teverelix #ClinicalTrials #Pharma
For the three months ended September 30, 2026, Medicus reported a net loss of $15.2 million, or $11.64 per share, compared with a loss of $16 million, or $56.18 per share, in the same period last year.
Medicus ended the quarter with $13.1 million in cash, cash equivalents and restricted cash, including $5 million in unrestricted cash and cash equivalents.
Bokhari said the third quarter marked a transformation for Medicus into a precision oncology-focused biotechnology company, with CD228V now its principal development priority. Medicus holds an exclusive worldwide licence to develop, manufacture and commercialize CD228V through a co-development agreement with Pfizer, which has provided $2 million in development funding.
The company is targeting initial clinical proof-of-concept in patients with relapsed, refractory or immunotherapy-resistant melanoma. The program is supported by an existing US investigational new drug application and a first-in-human Phase 1 study.
Medicus believes CD228V could potentially achieve an objective response rate above 30% in melanoma, although that target has yet to be demonstrated in clinical trials. Pfizer also has the option to fund all or part of development costs beginning with the first pivotal trial.
Medicus is also advancing plans to separate its SkinJect business through a proposed business combination with a special purpose acquisition company.
Meanwhile, for Teverelix, the company has submitted a proposed seamless Phase 2b/3 clinical trial protocol to the US Food and Drug Administration for advanced prostate cancer. The study is designed to enrol approximately 608 patients, subject to meeting predefined criteria to proceed.
Rather than fund the Teverelix study itself, Medicus intends to pursue an out-licensing agreement or another strategic partnership to advance the program.
#proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #CD228V #PrecisionOncology #Biotechnology #CancerResearch #Melanoma #Pfizer #SkinJect #Teverelix #ClinicalTrials #Pharma
Engelsk
USA
UTSKRIFT 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
SÖK TIDIGARE AVSNITT
Sök efter tidigare avsnitt från Proactive - Interviews for investors.
ANDRA EPISODER I DENNA PODCAST
Purepoint Uranium Group CEO Chris Frostad joined Steve Darling from Proactive to discuss the company's newly approved 2027 exploration programme with joint venture partner IsoEnergy at the Dorado Project in Saskatchewan's eastern Athabasca Basin.
The 50/50 joint venture has approved a programme of…
First Graphene Ltd (ASX:FGR, OTCQB:FGPHF) managing director and chief executive Michael Bell talked with Proactive about the company's joint development and commercialisation agreement with China's UNITEX Composite (Ningbo) Co Ltd, targeting graphene-enhanced carbon fibre composites and opportuniti…
Renforth Resources CEO Nicole Brewster joined Steve Darling from Proactive to discuss an updated Mineral Resource Estimate (MRE) for the company's Parbec Gold Deposit in Quebec, which outlines a combined 435,700 ounces of gold across Indicated and Inferred categories.
The updated estimate, prepare…
Webull Securities Australia chief executive Rob Talevski talked with Proactive about the move towards 23-hour trading on major US stock exchanges, what extended trading hours mean for Australian investors and whether the Australian Securities Exchange (ASX) could eventually follow suit.
With major…
Jonny White, sales & client manager at Ethical Screening and senior advisor at The Justice Company, talked with Proactive's Stephen Gunnion about the first six months of the JURY Global High Dividend UCITS ETF (LSE:JURY), growing investor interest, and its first portfolio rebalance.
White said…
Ansvarsfriskrivning: Podcasten och konstverket som är inbäddat på den här sidan är från Proactive, som är dess ägares egendom och inte anslutet till eller godkänt av Listen Notes, Inc.
REDIGERA
Tack för att du hjälper till att hålla databasen över podcaster uppdaterad.